Clinical Trial Update: A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update for FMC-376 in KRAS G12C-mutated solid tumors, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• FMC-376

Snippet

Sponsor: Frontier Medicines Corporation | Conditions: Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult | Phase 1, Phase 2 | Status: RECRUITING